Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates

Published: Tuesday, February 07, 2012
Last Updated: Tuesday, February 07, 2012
Bookmark and Share
The company announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.

The new addition was unveiled at the 1st annual Society for Laboratory Automation and Screening Conference, in San Diego.

The expansion of the Epigenetic Biochemical Toolbox increases the portfolio to over 35 validated enzymatic assays for the detection of post-translational modifications of histone H3 and p53. The assays cover all the major writer and eraser enzyme families including HDACs, Sirtuins, HATs, HMTs and demethylases. This newly expanded portfolio helps researchers explore epigenetics-based therapeutic candidates for cancer and neurodegenerative disorders.

"This new addition to our epigenetics portfolio is part of a series of innovations to create a full breadth of offerings to advance personalized medicine research," said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. "We are taking active steps to continue to transform PerkinElmer into one of the leading providers of technologies, services and products to enable researchers in this expanding market."

The new AlphaLISA(R) Epigenetic Cellular Detection Kits enable rapid and direct detection of endogenous modification of epigenetic marks on Histone H3, all in a one-well, no-wash assay format.

"The study of epigenetics is rapidly growing and presents opportunities for drug discovery, resulting in an increased need for high quality reagents," said Mark Roskey, vice president and general manager, Reagents, Life Sciences and Technology, PerkinElmer. "We now provide the most comprehensive reagent portfolio for epigenetic drug discovery. Our solutions are highly validated with detailed, ready-to-use protocols, and optimized for simplicity and throughput, marking our commitment to this expanding area of research."

PerkinElmer's epigenetic portfolio provides researchers access to fully validated reagents and assay development services that offer valuable time savings in the race to discover novel drug candidates. These highly specific reagents along with PerkinElmer's knowledge support for the development of epigenetic assays allow researchers to identify and characterize their lead compounds more quickly and efficiently.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PerkinElmer Collaborates with Waters on Chromatography Solutions
PerkinElmer, Inc. has announced a chromatography collaboration with Waters Corporation to deliver market leading software and premium instruments to PerkinElmer’s customers.
Wednesday, February 18, 2015
PerkinElmer, Sofie Biosciences Announce Benchtop PET Imaging Partnership
Preclinical PET imaging instruments in benchtop format help support high performance disease research, drug discovery and clinical translational applications.
Tuesday, June 10, 2014
Good Start Genetics, PerkinElmer Collaboration Expands Access to Genetic Carrier Screening Tests
Strategic agreement will broaden access to GoodStart Select™ tests to include obstetrics and gynecology and maternal fetal medicine physicians.
Monday, March 17, 2014
PerkinElmer Revenues Grow 4%
PerkinElmer, Inc. reported financial results for the fourth quarter ended December 29, 2013.
Monday, February 03, 2014
CAS and PerkinElmer Combine the Power of SciFinder and ChemBioDraw
New functionality will enable ChemBioDraw users to search in SciFinder, providing access to comprehensive content available in the CAS databases.
Tuesday, December 17, 2013
PerkinElmer Announces Strategic Alliance with Integromics
PerkinElmer becomes the sole worldwide distributor of Integromics’ software for the TIBCO Spotfire.
Tuesday, June 25, 2013
PerkinElmer to Host Revolutionaries for Global Health Summit
Company to assemble thought leaders to share pioneering personalized health research and innovations.
Wednesday, May 01, 2013
ViaCord® Collaborates with the Center for International Blood and Marrow Transplant Research®
PerkinElmer’s family cord blood banking business and international research organization collaborates to analyze quality and outcomes of cord blood stem cell units.
Wednesday, May 01, 2013
PerkinElmer and MGH Pathology Collaborate
Collaboration to develop a complete sequencing informatics system for cancer research.
Wednesday, September 12, 2012
PerkinElmer and TPM Biotech SDN. BHD. Partner to Validate Screening Application for Halal Food Products
Companies collaborate to explore potential applications of PerkinElmer’s Porcine Detection Kits and chromatography solutions for use in validating methods of testing food products for compliance with Halal certification regulations.
Tuesday, April 10, 2012
PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository
Companies team up to enable large-scale sequencing studies through more efficient automation and improving next generation sequencing sample access.
Tuesday, February 21, 2012
PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository
Rutgers University Cell and DNA Repository has adopted PerkinElmer’s technologies for automation of Next Generation Sequencing sample preparation.
Thursday, February 16, 2012
PerkinElmer to Acquire Caliper Life Sciences
PerkinElmer, Inc. announces that it has signed a definitive agreement to acquire Caliper Life Sciences, Inc. for a total net purchase price of approximately $600 million.
Wednesday, September 21, 2011
PerkinElmer Acquires Labtronics Inc.
The acquisition of Labtronics follows the recent purchase of informatics companies CambridgeSoft and ArtusLabs by PerkinElmer, both announced in March.
Sunday, May 22, 2011
PerkinElmer Announces Acquisition of Geospiza
The acquisition of Geospiza supports PerkinElmer’s growing offerings in Next Generation DNA Sequencing and Analysis Services, enabling researchers to explore the genomic origins of disease more effectively.
Monday, May 16, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos